Biogen (MIL:1BIIB) Cyclically Adjusted PB Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIL:1BIIB Biogen Inc MIL:1BIIB
50 GF Score
Price €188.62
GF Value €172.88
Valuation Fairly Valued
! 10 Warning Signs
View Full Analysis

What is Biogen Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Biogen  (MIL:1BIIB) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Biogen Cyclically Adjusted PB Ratio Related Terms


Biogen Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Biogen's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biogen Cyclically Adjusted PB Ratio Chart

Biogen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 3.32 1.85 1.75

Biogen Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.33 1.42 1.79 1.89 2.14

MIL:1BIIB vs OGN, AMRN, NSRX: Cyclically Adjusted PB Ratio Comparison

For the Drug Manufacturers - General subindustry, Biogen's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biogen Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biogen's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Biogen's Cyclically Adjusted PB Ratio falls into.


MIL:1BIIB
50GF Score
Biogen Inc MIL:1BIIB
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biogen Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Biogen's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Biogen's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=111.616/333.9520*333.9520
=111.616

Current CPI (Jun. 2026) = 333.9520.

Biogen Quarterly Data

Book Value per Share CPI Adj_Book
201609 49.547 241.428 68.535
201612 53.261 241.432 73.671
201703 50.547 243.801 69.238
201706 47.994 244.955 65.431
201709 51.394 246.819 69.537
201712 49.605 246.524 67.197
201803 54.093 249.554 72.387
201806 52.100 251.989 69.046
201809 58.797 252.439 77.783
201812 57.808 251.233 76.841
201903 63.062 254.202 82.846
201906 61.529 256.143 80.220
201909 70.556 256.759 91.768
201912 68.217 256.974 88.652
202003 68.295 258.115 88.361
202006 63.496 257.797 82.253
202009 59.536 260.280 76.388
202012 57.308 260.474 73.474
202103 60.244 264.877 75.955
202106 63.426 271.696 77.959
202109 63.916 274.310 77.813
202112 65.561 278.802 78.530
202203 68.371 287.504 79.417
202206 78.152 296.311 88.080
202209 90.500 296.808 101.826
202212 87.056 296.797 97.954
202303 87.638 301.836 96.963
202306 91.536 305.109 100.189
202309 94.384 307.789 102.407
202312 92.459 306.746 100.659
202403 96.745 312.332 103.442
202406 101.753 314.175 108.158
202409 100.603 315.301 106.554
202412 110.720 315.605 117.156
202503 107.291 319.799 112.039
202506 102.472 322.561 106.091
202509 105.629 324.800 108.605
202512 105.892 324.054 109.126
202603 109.674 330.213 110.916
202606 111.616 333.952 111.616

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Biogen (MIL:1BIIB) Overvalued in 2026?

Based on GuruFocus' analysis, Biogen stock appears to be overvalued. The current stock price of €188.62 is trading 9.1% above its estimated GF Value™ of €172.88. GuruFocus considers Biogen to be Fairly Valued.

Key valuation signals for MIL:1BIIB:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: €172.88 vs. price of €188.62 (9.1% above fair value)
  • GF Score™: 50/100 with 10 warning signs

No single metric tells the full story. See the MIL:1BIIB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Biogen Business Description

Address 225 Binney Street, Cambridge, MA, USA, 02142
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
50GF Score

Get the complete analysis for MIL:1BIIB

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€188.62
Price
€172.88
GF Value